This episode is brought to you by:

Brex. Brex began as the first corporate card for startups and now offers a full financial stack built for scale. Get 10-20x higher credit limits, uncapped rewards, easy deposits and payments, and expense management all in one. Grow your business faster with Brex.

MITIMCo. As the endowment office of MIT, MITIMCo searches for investment firms that are focused on achieving exceptional long-term investment returns. MITIMCo's goal is to create long-term relationships. They will partner with firms as early as Day 1 and do not ask for general partner economics in return. Visit MITIMCo’s website to learn more about their unconventional emerging manager approach, including examples of managers they have backed. While they only partner with a handful of new firms each year, they have also created and published resources for the broader universe of emerging managers to benefit from, making them even more unusual in the LP world. Visit www.mitimco.org to learn more.

Show Notes

[00:03:05] - [First question] - The current state of cancer treatment today writ large

[00:05:43] - What cancer is literally and how it becomes life-threatening

[00:06:38] - Why uncontrolled cell growth is so bad

[00:07:27] - The main three ways we currently treat cancer

[00:11:29] - Whether or not there are targeted ways we can treat cancer like mRNA

[00:14:08] - How we’ve historically detected cancer and what future detection could look like

[00:17:12] - Death rates of cancer in the US annually and the business side as it stands today

[00:18:20] - Key players in the cancer treatment space that serve patients

[00:19:13] - The pioneering technology that Novocure created to treat cancer

[00:22:38] - The mechanism that allows their tech to target the right cells

[00:25:35] - Overview of the actual procedure that takes place with their therapy

[00:28:36] - The impact and results of their new treatment method

[00:33:37] - A future where we can take this in a prophylactic and preventive sense

[00:34:44] - Why this approach to cancer treatment isn’t more widely known and accepted

[00:38:09] - Financials of Novocure and the opportunities it presents for their business

[00:43:10] - How they spend their R&D dollars and horizontal and vertical growth

[00:48:01] - Unique ways they spend their revenue to scale their business

[00:51:05] - Biggest criticisms of the size and scope of Novocure

[00:52:18] - Broader business lessons learned while building a cancer treatment company

[00:55:23] - The future of healthcare more generally and what has him most excited